We have detected that your browser is currently in "Compatibility mode".
To enjoy the best experience of this website, please change your browser settings (Tools => Uncheck "Compatibility View") or use another browser.
Date: 03.05 & 14.05
Time: 17:00 - 18:00
Location: Hall 10 - booth A04-1
Dr. Siegfried Throm, Director Research/Development/Innovation
The vfa, the Association of Researchbased Pharmaceutical Companies, is the trade organization of researchbased pharmaceutical companies in Germany. 45 leading research-based pharmaceutical companies are organized in the vfa. Together with their more than 100 subsidiaries and affiliated companies, they employ nearly 90,000 people in Germany.
After having studied pharmacy at the University of Heidelberg and having obtained his PhD Dr. Throm worked from 1983 up to 1986 in a hospital pharmacy. He then joined the pharmaceutical department of the Bundesverband der Pharmazeutischen Industrie (BPI) in Frankfurt. In 1995 he changed over to the newly founded German Association of Research-Based Pharmaceutical Companies (vfa) to become Head of Production, Quality and Environment. Since March 2001 Dr. Throm holds the position Director Research, Development, Innovation. He is i.a. member of the expert group Sci-entific, Technical, Regulatory Policy Committee of the European Fed-eration of Pharmaceutical Industries and Associations (EFPIA) and of the Biologicals Committee of the International Federation of Pharma-ceutical Manufacturers Associations (IFPMA).
François Hosotte, Plant Director
Ferring Pharmaceutical, Manufacturing Site - Switzerland
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China and is currently building new facilities in the US and India. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring's marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 50 countries and employ more than 4500 people throughout the world, while treatments are available in more than 90 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
With a Mechanical engineering background Francois Hosotte has joined the Pharmaceutical industry 20 years ago, coming from the automotive industry. He successively worked in Pharma, Cosmetic & Consumer Health, and Biotech activities.
Being involved at the beginning of his career in production and maintenance activities, he was confronted as a customer to many technical changes in the field of secondary packaging materials.
Later, heading manufacturing activities, in close contact with marketing and regulatory affairs, the challenge was to respond and anticipate the market and regulatory increasing needs. Solutions had to be developed and implemented to answer Consumer and Pharmaceutical requirements on secondary packaging like anti-counterfeiting, integrity, traceability etc.
Currently, leading the Ferring Pharma plant in Switzerland, F. Hosotte has been puting a specific focus on developing a true partnership with the packaging suppliers to develop the appropriate packaging solution and preparing a response to the future needs while leaving the Ferring packaging engineering team focussing on their core activities.
Dieter Mößner, Team Leader Customer Service
Carl Edelmann GmbH, Heidenheim/Germany
With its twelve production sites in Germany, Poland, France, Mexico, Hungary and China, the Edelmann Group is a leading provider of sophisticated and innovative packaging solutions made from board. The family business, founded in 1913, which is based in Heidenheim, Baden-Württemberg/Germany, represents the group of companies.
Edelmann produces pharmaceutical packaging, for premium consumer goods products, especially cosmetics, hair coloration, confectionery and cigarettes, as well as leaflets and labels.
Since 15 years, Dieter Mößner has been working as a team leader in the Prepress area and has been responsible for artwork services and for print data communication. His job is to consult customers and artwork agencies in artwork creation, print data communication and typesetting workflows.
He composed parts of the “Technical Guidelines Braille on folding cartons”, published by the German Folding Cartons Association FFI (www.ffi.de), and the guidelines “Braille on folding cartons”, published by the European Carton Makers Association ECMA (www.ecma.org). He is Convenor of CEN/TC 261/SC 5/WG 12 “Marking”. This working group at the European committee for standardisation CEN (www.cen.eu) has created the European standard EN 15823 “Braille on packaging for medicinal products”. It actually deals with the creation of a European standard on Tamper verification features for medicinal product packaging.
Currently the European standard EN 15823 is being transformed into an International standard ISO 17351 “Braille on packaging for medicinal products” within ISO/TC 122 packaging. It is dealt with as project within ISO/ TC 122/WG 9 “Accessible design” with Dieter Mößner / Germany as project leader.
Dieter Mößner is also Chairman of the German working groups NA 115-03-01 AA “Braille on packaging” and “Tamper verification features for medicinal product packaging” and Vice-chairman of the packaging standards committee NAVp ( www.din.navp.de ) at the German Standards Institute DIN ( www.din.de ).